Genentech/Wellcome TPA litigation
Executive Summary
On Oct. 31, the British Court of Appeals rejected Genentech's broad patent claims covering its clot dissolver, TPA. The decision upholds an earlier lower court ruling. Genentech said it does not believe the decision will affect Genentech's TPA patent position in the U.S. Genentech has been in litigation with Wellcome since Genentech was granted a U.K. patent and a subsequent U.S. recombinant patent. Genentech has a patent infringement suit against Wellcome pending in Delaware Federal Court ("The Pink Sheet" Aug. 29, T&G-8).
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.